Comparison of Different Invasive Devices for the Treatment of Urinary Incontinence after Radical Prostatectomy

Table 3

36 prospective clinical trials included in the analysis: baseline values. Number of cases; mean ± SD or median and (range).

Author	No. of patients	Treatment groups (A, B, C, D, and E)	N pad/day (pre)	1 h pad test (g) (pre)	24 h pad test (g) (pre)	% Severe UI (>6) (pre)	% Moderate UI (3–5) (pre)	% Mild UI (1–2) (pre)	ICIQ-UI-SF (pre)
Suzuki et al. [10]	4	B	4.0 ± 0.8	—	—	—	—	—	—
Suzuki et al. [10]	4	B	3.5 ± 1.3	—	—	—	—	—	—
Migliari et al. [11]	49	B	—	—	—	25.0%	69.0%	6.0%	—
Bauer et al. [31]	115	B	—	—	272.0 (42–1600)	—	—	—	14.9 (8–22)
Bauer et al. [30]	137	B	4.9 (1–24)	124.4 (11–585)	—	31.0%	52.3%	16.7%	16.4 (5–22)
Migliari et al. [37]	9	B	—	—	—	—	—	—	—
Bauer et al. [12]	124	B	4.0 ± 1.1	119.5	292.2 (45–1200)	24.2%	48.4%	15.3%	17.0 ± 3.6
Ferro et al. [28]	29	B	2.2 ± 1.4	—	128.6 ± 71.9	—	72.4%	27.6%	14.3 ± 3.6
Galiano et al. [27]	52	B	2.2 ± 1.0	—	123.5 ± 107.8	—	—	—	—
Leruth et al. [23]	173	B	—	—	—	48,6%	30.0%	21.4%	—
Zaragoza et al. [22]	4	B	4.0 (3–5)	—	—	—	100%	—	—
John et al. [21]	16	B	7.0 (2–12)	—	—	38.0%	—	—	—
Collado et al. [15]	94	B	—	—	93.0 (12–507)	—	—	—	14.4 (5–21)
Collado et al. [14]	27	B	1.9 (1–3)	—	—	—	—	—	12.3 (8–21)
Trigo Rocha et al. [36]	40	D	4.0 ± 0.9 (3–10)	—	—	87,5%	12.5%	—	—
Correia Lima et al. [32]	15	D	—	—	135.19 ± 159.54	—	—	—	16.7 ± 2.7
Lai et al. [24]	129	D	5.2 ± 0.3 (1–15)	—	—	—	—	—	—
Trigo Rocha et al. [20]	25	E	4.7 ± 1.7	—	—	—	—	—	—
Bauer et al. [41]	24	B	4.5 (1.5–12)	89.5 (21–150)	—	—	—	—	16.9 (5–22)
Noordhof et al. [35]	143	E	3.5 (2–5)	—	—	35.0%	39.8%	25,.%	—
Seweryn et al. [34]	38	C	6.7 (2–10)	—	747.0 (230–1600)	57.8%	34.2%	7.9%	—
Kim et al. [33]	64	C	3.4 ± 2.0	—	—	14.1%	43.8%	42.2%	18.6 ± 2.61
Renè Yiou et al. [25]	20	E	2.9 ± 1.0	—	345.1 ± 308.4	—	—	—	16.8 ± 2.6
Renè Yiou et al. [29]	40	B	2.5 ± 1.2	—	—	—	—	—	14.4 ± 4.4
Hoda et al. [26]	124	C	8.8 ± 3.8 (3–18)	—	725 ± 372 (110–2300)	69.6%	30.4%	0%	—
Hoda et al. [26]	99	C	7.1 (3–12)	—	681.0 (100–2000)	70.7%	29.3%	0
Martens et al. [19]	29	E	4.8 (3–6)	—	—	—	—	—	—
Introini et al. [18]	66	C	—	—	—	—	—	—	—
Le Portz et al. [17]	93	B	1.8 (1–4)	—	109.1 ± 116.37	—	—	—	—
Dikranian et al. [16]	20	A	3.4 (2–6)	—	—	—	—	—	—
Dikranian et al. [16]	16	B	4.0 (2–7)	—	—	—	—	—	—
Gregori et al. [13]	11	E	—	—	543.6 (80–1300)	18.0%	64.0%	18.0%	—
Cestari et al. [9]	120	B	—	—	—		—	—	—
Van Uhm et al. [38]	10	A	—	—	17.3 (6.4–20.9)	—	—	—	10.0 (9.0–12.0)
Cestari et al. [39]	60	B	1.1 ± 1.2	—	—	—	—	—	4.8 ± 4.6
Stephen J et al. [40]	15	B	—	—	—	—	—	—	—
Crivellaro et al. [21]	46	E	5.1 (5–2)	—	—	—	89.0%	11.0%	—
Crivellaro et al. [21]	38	B	3.2 (3–1)	—	—	—	72.0%	28.0%	—
Queissert et al. [43]	12	C	4.0	—	240 (72–125)	—	—	—	16.0

Note. UI = urinary incontinence. Treatment group: A = bulking agent, B = fixed sling, C = adjustable sling, D = artificial sphincter, and E = ProACT. Grey horizontal rows represent the second arm of treatment in the same trial. Severe UI is defined as > 6 UI episodes, moderate 3–5 UI episodes, and mild 1–2 UI episodes daily.